ArticleNeurology and therapy2024

Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis.

Fredrik N Albach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.